The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sp should climb higher when DOW opens... great takeover news...
Times of India suggest Lupin may have thrown it's hat in ring could bid $500m for Sinclair.
Trading Update London, 5 August 2015 Sinclair IS Pharma plc (SPH.L), ("Sinclair" or the "Group") the international specialty pharma company, announces a trading update for the financial year ended 30 June 2015. The Group has had a strong second half to the year, from both a financial and operating perspective. Trading has followed the historic seasonality in Sinclair's sales, with peak sales in late spring. This has been partially offset by the continued weakness in the Euro. Revenues for the full year were £75.9 million, compared to £63.6 million last year representing reported growth of 19% and 24% on a constant currency basis (revenue at constant currency £79.0 million). Like for like1 growth for the year was 8% compared with 4% for FY14 demonstrating the impact of the faster growth aesthetics portfolio. Revenue in the aesthetic portfolio grew strongly reaching £35.8 million for the year (47% of total revenues) representing 67% reported growth over the £21.4 million achieved last year and 19% LFL growth. Despite a delay to Russian approval and FX headwind, Silhouette revenues beat budget in reaching £8.7 million for the year (120% LFL) as a result of a strong performance in Europe and in Brazil. Most significantly Silhouette Instalift received FDA approval in April 2015 and the company is now building its US affiliate ahead of a full launch now scheduled for early 2016. Independent market research suggests Silhouette Instalift has substantial sales potential in the US (with estimated peak sales in excess of US$200 million) and will be a significant driver of Group earnings over the next few years. Silhouette Soft was also approved in South Korea in March and in Russia in June 2015. In July 2015 an extended indication to include neck and eye brow lifting was approved for Europe, increasing the area of approved use for Silhouette. Propelled by these positive developments, the Board remains enthusiastic with Silhouette's growth prospects and market potential. Perfectha delivered revenues of £8.2 million for the year (13% LFL) growth, with 22% growth in H2 compared to the first six months. Product growth was particularly strong in Europe and Intercontinental but offset by a decline in South Korea in a tough market environment. The FY16 growth rate is expected to be similar to FY15 as South Korea recovers and Perfectha Lido is launched in Europe in H2 FY16. Perfectha G (sexual function) remains on track for a launch in 2017. Ellansé also recorded a stronger second half reaching sales of £4.5 million for the year (1% LFL) but 50% growth in H2 over H1. Post-acquisition de-stocking in South Korea negatively impacted sales particularly during H1, which combined with a weak Russian market environment resulted in Ellansé performance below Board expectations for the year. Nonetheless, consistent robust growth in physician user base in Europe (298% LFL), a strong
A very positive step: http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12329826.html
Why is everyone selling! You should see the chart
As a guess some of the institutional guys are taking some profit at these levels or top slicing. Most have large positions so makes sense to cash in 10-20% at price goes up. Good luck all! DYOR.
Does anyone know why we had such large sells today? For the last few weeks buying has been outstripping sells
Heavy volume last few days hoping bid will be around 60p.Pharma flavour of the month.not long to wait now .
Price action encouraging given how long this possible "auction" process is taking. There seems to be some reasonable buyers around the 36p level? Fingers crossed we will hear something positive in the next few weeks, meanwhile I'm a happy holder.
anyone know what is happening with the bid offer and what the time limits are?
Out this Tuesday, coming...
(Thanks ArianParod HL) Upto 10 potential buyers MARKET REPORT: Buyers lining up for Sinclair sale as shares rise 12% to three-year highGEOFF FOSTER FOR THE DAILY MAILPUBLISHED: 015, 26 November 2014 | UPDATED: 015, 26 November 2014No less than ten interested parties are believed to have shown an interest in Sinclair IS Pharma, which has put itself up for sale.Shares of the aesthetics and skincare company rose 4p or 12 per cent to a three-year high of 36.5p after it was revealed it has appointed Rothschild to explore means of realising shareholder value. In other words, find a buyer.Private equity players and Swiss food giant Nestle, which earlier this year set up a specialised medical skin care division after acquiring the rights to sell certain products in the US and Canada from Valeant Pharmaceuticals for £840million cash, are rumoured to be heading the queue of buyers willing to pay up to about £300million or 60p-plus a share for the company, which owns an anti-ageing treatment that could turn out to be better than Botox.Promising: No less than ten interested parties are believed to have shown an interest in Sinclair IS Pharma, which has put itself up for saleIt was on the cards that Sinclair would be re-rated following the recent stonking £42billion bid for Botox giant Allergan.Sinclair owns Silhouette, a company which manufactures Silhouette Soft, a £1,200 anti-ageing treatment that uses dissolvable thread to beat wrinkles. Broker N+1 Singer is bullish and says the company’s exciting product portfolio could bring substantial value to a potential acquirer.Major Sinclair shareholders include heavyweights Toscafund, Lansdowne and George Soros. He lifted his stake above 5 per cent in June by acquiring more stock at 32p a pop.
i reckoned another 10% or more rise tomorrow.
Soros is not a mug ,he must have known something to invest here i wish i put all my money in here .
To clear at 38p!
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12162135.html
I presume that the largest shareholder wants their return sooner rather than later. Must be attractive to any number of larger competitors wanting a fairly broad bridgehead on which to build and expand.
Sculptra is better and lasts longer than botox, the potential for this product is huge! A massive game changer for our company. Just hope we aren't going to be taken out on the cheap! Actavis to buy Botox maker Allergan for $66B
Statement re AGM and commencement of offer period Tue, 25th Nov 2014 07:00 RNS Number : 8731X Sinclair IS Pharma PLC 25 November 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION Sinclair IS Pharma plc ("Sinclair" or "the Company") AGM Statement, trading update, announcement of strategic review and commencement of offer period. Grahame Cook, Chairman of Sinclair, will make the following statement at the Company's AGM which will be held later today. Sinclair has a market leading aesthetics dermatology portfolio. We also have a significant product pipeline which includes Flammacerium that has already been granted orphan drug status in the United States. The Board of Sinclair believes the portfolio has significant and sustainable growth potential across the world. The Board of Sinclair is pleased to report that the Company continues to trade well and in line with the Board's expectations. The Board believes that industry recognition of the Company's growth prospects explains the significant attention the Company is receiving from a number of international companies, many of which are interested in some form of, co-operation, including: (co)-promotion; licensing of products; repatriation of distribution agreements; development collaborations; and merger and acquisition opportunities. As a result of the deliberation process arising out of these opportunities, the Board recognises that there may be organisations better placed to build on the successes to date. Accordingly, the Board has decided to appoint Rothschild to assist it in evaluating the optimum way to realise the considerable value in the Company which may, or may not, include the sale of all or part of the Company. The Board believes that Sinclair has a secure future as an independent business and will only engage with those willing to recognise and support the Company's significant growth potential. The UK Takeover Panel ("the Panel") has agreed that any such discussions with third parties may be conducted within the framework set out in Note 2 on Rule 2.6 of the Takeover Code (the "Code"). The Panel has granted a dispensation from the requirements of Rules 2.4(a), 2.4(b) and 2.6(a) of the Code such that any interested party will not be required to be publicly identified as a result of this announcement (subject to note 3 to Rule 2.2 of the Code) and will not be subject to the 28 day deadline referred to in Rule 2.6(a), for so long as it is participating in discussions with Sinclair.
Elsewhere, skin-focused pharma firm Sinclair IS Pharma (SPH) is tipped to grow earnings by 37% in the year to June 2015 and 53% the following year. That's impressive, and a forward PE ratio of less than 17 is an unfair discount to the sector. Directors certainly think so. They've just spent over £200,000 on shares in the company.
Sinclair is moving ahead nicely and attracting bug buying trades..... excess of 13 million today! Got to be an excellent buy just on fundamentals, the added possibility of a take over, just adds spice!
huge trades for here,going thro,on the cnbc ticker,not showing up?one for 7mill.
Looking positive: http://www.sinclairispharma.com/media/24874/141028%20investor%20ppt.pdf
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12118866.html